Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biomedical

Rutgers Robert Wood Johnson Medical School Aims to Educate and Inspire the Next Generation of Health Care Innovators

Gregg Khodorov and Julia Tartaglia, second-year medical students, are co-presidents of Rutgers Biomedical Entrepreneurial Network. [Photo: Nick Romanenko, Rutgers University]

New Brunswick, NJ, October 10, 2017 — Carla Cantor reports that John Dutton learned his first lesson in entrepreneurship the hard way.

“I had a great idea for a medical product, a patent and a business plan — and still I got scooped,” says Dutton, who was 22 and a researcher at Children’s Hospital of Philadelphia when he watched another company make good with a variation of his invention.

The following year, as a first-year student at Rutgers Robert Wood Johnson Medical School, Dutton and two classmates, Steven Shterenberg and Matthew Michel, launched Rutgers Biomedical Entrepreneurial Network (BEN). Continue reading

Rutgers Health Care Improves Lives, Boosts Economy; Research Generates $31.5 Million in Royalty Income

New Brunswick, NJ, June 6, 2017 — Rutgers University is emerging as a national leader in academic health care, providing top-level services for patients while also boosting the economy statewide, according to a new economic impact report issued by the university.

Rutgers spent more than $684 million in patient care, delivering medical, dental, nursing and psychological services provided by clinicians and specialists and through research and more than 350 clinical trials in fiscal year 2016.

Rutgers Health, the university’s patient care organization that employs more than 1,300 health care professionals, handled 2.1 million patient visits to all locations in fiscal year 2016. Continue reading

Sen. Menendez Visits Rutgers Cancer Institute to Illustrate Impact of Trump Proposed Budget Cuts on Lifesaving Biomedical Research that Leads to New Cures, Treatments

Sen. Bob Menendez and (l.) Dr. Steven Libutti

New Brunswick, NJ, April 13, 2017 — During a visit yesterday to the Rutgers Cancer Institute of New Jersey, U.S. Senator Bob Menendez and several of the state’s top biomedical researchers and experts, outlined the devastating impact the Trump Administration’s proposed budget cuts to the National Institutes of Health (NIH) would have on lifesaving biomedical research, and treatments of diseases and neurological disorders.

New Jersey is the nation’s second largest recipient of NIH funding in the nation.

“A budget is a reflection of priorities,” said Sen. Menendez.  “The cuts proposed by the Trump Administration send a message that the research being done right here by some of nation’s most brilliant minds is not a priority.”

“It says the breakthrough discoveries that could potentially help someone like my mother in her fight against Alzheimer’s or give a terminally-ill child a shot at a healthy, happy life – is not worthy of federal investment,” Menendez added.  “That’s not a message I want to send.” Continue reading

NJIT’s Biomedical Engineering Program Ranked #1 Best Value in New Jersey

Newark, NJ, April 10, 2017 — The New Jersey Institute of Technology (NJIT) offered the best value biomedical engineering program in 2016 for undergrads in New Jersey according to BestValueSchools.com.

This program is also ranked eighth nationally. NJIT’s biomedical engineering program is part of the Newark College of Engineering (NCE), the oldest and largest professional engineering school in the United States.

Rankings were determined by a variety of factors including graduation rate, accreditation date, degree and engineering popularity and net price. Continue reading

Trump’s Plan to Cut NIH Funding for Biomedical Research Hits Opposition in Congress

Washington, DC, April 5, 2017 — Robert Pear reports in The New York Times that a proposal by President Trump to cut federal spending for biomedical research by 18 percent — just months after Congress approved bipartisan legislation to increase such spending — has run into a buzz saw on Capitol Hill, with Republicans and Democrats calling it misguided.

Mr. Trump is asking Congress to provide $25.9 billion for the National Institutes of Health for the fiscal year that starts on Oct. 1.  That represents a cut of $5.8 billion, or 18 percent, from the agency’s current spending level of $31.7 billion.

A week after making that proposal, Mr. Trump told Congress that he wanted to cut spending at the N.I.H. by $1.2 billion in the current fiscal year, mostly by reducing research grants. Continue reading

NJIT’s Biomedical Engineering Program Ranked #1 Best Value in New Jersey

Newark, NJ, March 14, 2017 — The New Jersey Institute of Technology (NJIT) offered the best value biomedical engineering program in 2016 for undergrads in New Jersey according to BestValueSchools.com.

This program is also ranked eighth nationally. NJIT’s biomedical engineering program is part of the Newark College of Engineering (NCE), the oldest and largest professional engineering school in the United States.

Rankings were determined by a variety of factors including graduation rate, accreditation date, degree and engineering popularity and net price. Each equally weighted metric was combined for an overall score, indicating the quality and cost expected from the ranked programs. Continue reading

Save the Date! ‘New Jersey Rare Disease Day 2017’ Set for February 27 in Trenton

Rare Disease DayTrenton, NJ, January 29, 2017 — New Jersey’s rare disease community will gather to celebrate Rare Disease Day 2017 on Monday, February 27 from 9:00 a.m. to 12:00 p.m. at the New Jersey Business and Industry Association (NJBIA) at 10 West Lafayette Street in Trenton.

The half-day event will be sponsored by BioNJ, the HealthCare Institute of New Jersey (HINJ), New Jersey Rare Disease Alliance and NORD.

The morning will begin at 9:00 a.m. with coffee, pastries and networking, followed by speakers from the rare disease community, including patients, patient advocates, legislators, biomedical healthcare professionals and life sciences community leaders. Continue reading

Rutgers’ Ronke Olabisi Aims to Develop Biomaterials that Can Speed Healing in Space and on Earth

Ronke Olabisi

Ronke Olabisi

New Brunswick, NJ, January 25, 2017Ronke Olabisi once dreamed of becoming an astronaut.  Now she’s conducting research that could help space travelers and Earth-dwellers heal faster and stay healthy.

“If healing people faster on Earth is going to be helpful, then it’s really going to be helpful in space,” said Olabisi, an assistant professor in Rutgers’ Department of Biomedical Engineering. “Spaceflight affects every single system.”

Bones, muscle and other tissues gradually break down in space, posing major problems for anyone wanting to go to Mars and beyond, said Olabisi, who works in the School of Engineering. Continue reading

Dr. Steven Libutti to Serve Dual Rutgers Roles: Cancer Institute Director and Rutgers Biomedical and Health Sciences Vice Chancellor

Dr. Steven K. Libutti

Dr. Steven K. Libutti

New Brunswick, NJ, November 18, 2016 — Aiming to further propel scientific discovery as well as augment and expand comprehensive cancer services for patients through collaborative efforts with Rutgers and RWJBarnabas Health, Steven K. Libutti, M.D., FACS, has been named to serve in the dual positions of Director of Rutgers Cancer Institute of New Jersey and of Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences.

When he takes on his new roles in early 2017, Dr. Libutti will be the third permanent director in the 25-year history of Rutgers Cancer Institute of New Jersey and will take over for Bruce G. Haffty, MD, who has been serving as interim director and will continue his role as Chair of Radiation Oncology.

Dr. Libutti also will have an appointment as a Professor of Surgery at Rutgers Robert Wood Johnson Medical School. Continue reading

Rutgers Biomedical Chancellor Brian Strom’s Paper Explores Why Clinical Trial-Data Sharing Off to a Slow Start

Dr. Brian Strom

Dr. Brian Strom

New Brunswick, NJ, November 2, 2016 — For many years, doctors, scientists and researchers have urged that clinical drug trial data be shared to accelerate medical advances in treating multiple diseases.

But two years after free patient data became available in a major data-sharing project, the biggest surprise is how little it is being used.

“Given the risks patients are taking and given the data being collected, there’s an ethical imperative to make maximum use of it,” said Brian L. Strom, chancellor of Rutgers Biomedical and Health Sciences. “That’s why it’s frustrating that more people are not using it and we don’t fully know why.” Continue reading